StockData
Xeris Biopharma Holdings, Inc. logo

Xeris Biopharma Holdings, Inc. (XERS) stock

XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$16.99+0.19 (+1.13%)

Close on Nov 18, 2026Market cap $3.10BP/E –Yield –

Xeris Biopharma price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Xeris Biopharma's price to sales ratio was 8.5× on Nov 11, 2026, against 4.5× a year earlier. Over the last 5 years it ranged from 1.5× to 8.5×, with a median of 2.9×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20268.5×+3.7
2025Dec 31, 20254.9×+2.2
2024Dec 31, 20242.7×+0.6
2023Dec 29, 20232.1×+0.3
2022Dec 30, 20221.8×−3.6
2021Dec 31, 20215.5×–

More Xeris Biopharma figures

See a number that looks wrong?